| ||
| ||
| Allergan shares jump after Botox migraine approval Reuters By Lewis Krauskopf and Ransdell Pierson NEW YORK (Reuters) - Allergan Inc's (AGN.N) shares jumped more than 4 percent on Monday after the company won US approval to market its blockbuster anti-wrinkle Botox injection as a treatment for chronic migraine ... See all stories on this topic » | ||
| Glaxo Forms Alliance to Work on Gene Therapy for Rare Diseases Bloomberg By Albertina Torsoli - Mon Oct 18 14:00:02 GMT 2010 GlaxoSmithKline Plc, the UK's largest drugmaker, formed an alliance with two Italian groups, Fondazione Telethon and Fondazione San Raffaele, to develop treatments for rare genetic disorders. ... See all stories on this topic » | ||
| No Single Diet Best for Preventing Breast Cancer CalorieLab Calorie Counter News Eating a healthy diet is one factor in breast cancer risk reduction, but researchers have yet to pinpoint a specific diet that is best. Overall, a diet rich in plant foods (fruits, vegetables, and whole grains) that is low in saturated and trans fats ... See all stories on this topic » | ||
| ||
| ||
| Justice Department Files Suit Against Blue Cross Blue Shield Of Michigan Wall Street Journal By Brent Kendall Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--The US Justice Department on Monday filed an antitrust lawsuit against Blue Cross Blue Shield of Michigan, alleging that provisions of its agreements with hospitals are anticompetitive. ... See all stories on this topic » | ||
| ||
| Kroger and Walmart Great Value Frozen Veggie Recall: Glass Fragment Risk AboutLawsuits.com Certain types of Wal-Mart and Kroger frozen vegatables have been recalled due to the possibility that they may contain small glass fragments. The frozen veggies recall was announced on October 15 by the manufacturer, the Pictsweet Company of Bells, ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment